Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: Its relationship to clinicopathological parameters

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 12, 2013, Pages 2835-2845

  Luo, Bin ^a,b   Yun, Xiang ^c   Fan, Rong ^d   Lin, Yong Da ^a,b   He, Shu Jia ^a   Zhang, Qing Mei ^a   Mo, Fa Rong ^a   Chen, Fang ^b   Xiao, Shao Wen ^d   Xie, Xiao Xun ^a,b  

^a Department of Histology and Embryology School of Pre clinical Medicine   (China)

^b Central Laboratory of Pre clinical Medicine   (China)

^c Departments of Pediatrics   (China)

^d GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer testis antigen; Colorectal cancer; Oy Tes 1

Indexed keywords

ACRBP PROTEIN, HUMAN; AUTOANTIBODY; CANCER TESTIS ANTIGEN; CARRIER PROTEIN; MESSENGER RNA; TUMOR MARKER;

ADENOMA; ADULT; AGED; ARTICLE; BLOOD; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COLORECTAL CANCER; COLORECTAL TUMOR; FEMALE; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; MIDDLE AGED; OY-TES-1; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; VERY ELDERLY;

CANCER TESTIS ANTIGEN; COLORECTAL CANCER; OY-TES-1;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CARRIER PROTEINS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84888803756     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Tebbutt NC, Cattell E, Midgley R, Cunningham D and Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000-1015.
3. Mosolits S, Nilsson B and Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines 2005; 4: 329-350.
4. Scanlan MJ, Simpson AJ and Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1.
5. Caballero OL and Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-2021.
6. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJ, Old LJ, Camargo AA and Vasconcelos AT. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009; 37: D816-819.
7. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT and Old LJ. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30.
8. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ and Gnjatic S. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 2008; 105: 1650-1655.
9. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y and Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005; 11: 1809-1814.
10. Alves PM, Lévy N, Bouzourene H, Viatte S, Bricard G, Ayyoub M, Vuilleumier H, Givel JC, Halkic N, Speiser DE, Romero P and Lévy F. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother 2007; 56: 839-847.
11. Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, Aoe M, Nakamura S, Higashi T, Hiraki A, Wada H, Kumon H, Old LJ and Nakayama E. Identification binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci U S A 2001; 98: 3282-3287.
12. Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth AA, Mhawech-Fauceglia P, Qian F, Schneider S, Sharma S, Driscoll D, Lele S, Old LJ, Nakayama E and Odunsi K. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol 2006; 29: 903-910.
13. Okumura H, Noguchi Y, Uenaka A, Aji T, Ono T, Nakagawa K, Aoe M, Shimizu N and Nakayama E. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T cell. Microbiol Immunol 2005; 49: 1009-1016.
14. Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik JT, Larson B, Girard L, Schorge JO and White MA. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res 2010; 70: 7652-7661.
15. Cen YH, Guo WW, Luo B, Lin YD, Zhang QM, Zhou SF, Luo GR, Xiao SW and Xie XX. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow derived mesenchymal stem cells. Cell Biol Int 2012; 36: 917-922.
16. Kanemori Y, Ryu JH, Sudo M, Niida-Araida Y, Kodaira K, Takenaka M, Kohno N, Sugiura S, Kashiwabara S and Baba T. Two functional forms of ACRBP/sp32 are produced by pre-mRNA alternative splicing in the mouse. Biol Reprod 2013; 88: 105.
17. Sobin LH, Gospodarowicz MK and Wittekind C. TNM Classification of Malignant Tumors. 7th edition. Oxford: Wiley-Blackwell, 2009. pp: 100-105.
18. Zhou SF, Xie XX, Bin YH, Lan L, Chen F and Luo GR. Identification of HCC-22-5 tumor-associated antigen and antibody response in patients. Clin Chim Acta 2006; 366: 274-280.
19. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ and Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-8062.
20. Bellati F, Napoletano C, Tarquini E, Palaia I, Landi R, Manci N, Spagnoli G, Rughetti A, Panici PB and Nuti M. Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. Eur J Cancer 2007; 43: 2621-2627.
21. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N and Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92: 856-860.
22. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC and Old LJ. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000; 85: 460-465.
23. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM and Beer DG. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1: 304-313.
24. Mathieu MG, Linley AJ, Reeder SP, Badoual C, Tartour E, Rees RC and McArdle SE. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. Cancer Immun 2010; 10: 2.
25. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, Hellerbrand C, Clavien PA, Moch H and Jochum W. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer 2009; 124: 352-357.
26. Yokoe T, Tanaka F, Mimori K, Inoue H, Ohmachi T, Kusunoki M and Mori M. Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. Cancer Res 2008; 68: 1074-1082.
27. Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, Pezzani L, Fratta E, Fonsatti E, Di Giacomo AM, Nicotra MR, Natali PG, Altomonte M and Maio M. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol 2006; 207: 58-66.
28. Qiu G, Fang J and He Y. 5' CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC. Clin Biochem 2006; 39: 259-266.
29. Wolpin BM and Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008; 134: 1296-1310.
30. Ulanska J, Dziki A, Langner E and Wronski W. Risk factors in the recurrence of the colorectal cancer. Acta Chir Iugosl 2002; 49: 41-43.
31. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M and Willett C. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994.
32. Ianosi G, Mercut D, Neagoe D, Ianosi S, Drighiciu C, Resceanu A, Andritoiu A and Manolache A. Histopathological factors as predictors for survival in colon and rectal cancers. Rom J Morphol Embryol 2008; 49: 365-369.
33. Kinzler KW and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
34. Bond JH. Clinical evidence for the adenoma-carcinoma sequence, and the management of patients with colorectal adenomas. Semin Gastrointest Dis 2000; 11: 176-184.
35. Leslie A, Carey FA, Pratt NR and and Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002; 89: 845-860.
36. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E and Monden M. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004; 64: 2199-2204.